secwatch / observer

8-K filed October 23, 2024, 7:59 PM ET ticker CNSP CIK 0001729427

regulatory confidence high sentiment negative materiality 0.80

CNS Pharma faces Nasdaq delisting for bid price deficiency; hearing Nov 5

CNS Pharmaceuticals, Inc.

Received Nasdaq notice on Sept 12, 2024, for failing minimum $1.00 bid price for 30 consecutive days.
Ineligible for 180-day cure period due to reverse stock splits >250:1 cumulative ratio in prior two years.
Hearing before Nasdaq Panel scheduled for Nov 5, 2024; automatically stays suspension or delisting pending hearing.
No assurance that Panel will grant an additional compliance extension beyond the hearing date.

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001683168-24-007304
form_type: 8-K
ticker: CNSP
cik: 0001729427
company_name: CNS Pharmaceuticals, Inc.
filed_at: 2024-10-23T23:59:59+00:00
discovered_at: 2026-05-14T18:03:09.386214+00:00
generated_at: 2026-05-30T11:07:35.897829+00:00
sec_items: ["8.01"]
event_type: regulatory
sentiment: negative
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001683168-24-007304
json_url: https://secwatch.observer/filing/0001683168-24-007304.json
markdown_url: https://secwatch.observer/filing/0001683168-24-007304.md
text_url: https://secwatch.observer/filing/0001683168-24-007304.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824007304/0001683168-24-007304-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316824007304/cns_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

LESL

Leslie's regains Nasdaq compliance for minimum market value of publicly held shares

Leslie's, Inc. June 1, 2026, 4:28 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

OTLK

Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days

Outlook Therapeutics, Inc. June 1, 2026, 9:15 AM ET regulatory Items 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

SLXN

Silexion Therapeutics completes 1-for-10 reverse share split; warrants adjusted

Silexion Therapeutics Corp May 29, 2026, 7:00 AM ET regulatory Items 3.03, 5.03, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

Richtech Robotics receives Nasdaq delisting notice for late Q1 10-Q filing

RICHTECH ROBOTICS INC. May 28, 2026, 4:49 PM ET regulatory Items 3.01, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

MNKD

FDA releases MannKind from Afrezza malignancy study; sBLA for children PDUFA May 29

MANNKIND CORP May 28, 2026, 8:37 AM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

SNAL

Snail receives Nasdaq extension to Sept 22, 2026 to regain listing compliance

Snail, Inc. May 27, 2026, 4:25 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

BBIO

FDA accepts NDA for BBP-418 with Priority Review; PDUFA Nov 27, 2026

BridgeBio Pharma, Inc. May 27, 2026, 4:01 PM ET regulatory Items 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

JAGX

Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027

Jaguar Health, Inc. May 27, 2026, 9:10 AM ET regulatory Items 7.01, 8.01, 9.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001683168-24-007304

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.